Pivotal Practice Views with the Oncology Brothers
Targeted Oncology's Pivotal Practice Views with the Oncology Brothers is a video series that focuses on recently-approved, practice-changing treatment options across tumor types.
Along with the Oncology Brothers, Paolo Tarantino, MD, discuss the phase 3 EMERALD study of elacestrant versus standard of care endocrine therapy for ER+, HER2- metastatic breast cancer (MBC). Their conversation focuses on the implications of recently published data demonstrating that elacestrant provides a PFS benefit across clinically meaningful subgroups of patients with ESR1m, ER+, HER2- MBC, including those with endocrine-sensitive disease.
Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.
Read More
FDA Approval of Zanubrutinib (ALPINE & SEQUOIA Study)
March 14th 2024Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the FDA approval of zanubrutinib and where it fits in clinical practice, highlighting data from the ALPINE and SEQUOIA studies.
Read More
Updates in HR+ Breast Cancer Treatment: Expert Perspectives on CAPItello-291
February 12th 2024Hope Rugo, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss data from CAPItello-291 on capivasertib and how it has changed the treatment landscape in HR+ breast cancer.
Read More
The Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Jonathan E. Rosenberg, MD, to discuss recent data from a phase 2 study investigating enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic bladder cancer.
Read More
